Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,819 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Media Clear all

Conditions: Child Abuse, Child Neglect, Child Maltreatment
Interventions: iLook Out for Child Abuse; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 35,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Postpartum Depression, Parenting
Interventions: Social Media Intervention, Traditional In-Person Intervention; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 15 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Heart Failure
Interventions: Magnetic Resonance Imaging with or without Contrast; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
Interventions: citalopram hydrobromide, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 198
States / cities: Augusta, Georgia • Aurora, Illinois • Bloomington, Illinois + 126 more

Conditions: Gestational Weight Gain, Postpartum Weight Retention
Interventions: electronic intervention during pregnancy and postpartum, electronic intervention during pregnancy, Control; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 1,641 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Acute Otitis Media
Interventions: AR01, Placebo Comparator; Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 2 Months to 18 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 21
States / cities: Phoenix, Arizona • Bakersfield, California • Fresno, California + 16 more

Conditions: Chronic Low-back Pain, Degenerative Disc Disease
Interventions: CELZ-201-DDT, Placebo; Drug · Other
Lead sponsor: Creative Medical Technology Holdings Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: End Stage Renal Disease
Interventions: Theranova 400 dialyzer, Elisio-17H dialyzer; Device
Lead sponsor: Vantive Health LLC; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 20
States / cities: Corona, California • Riverside, California • Bloomfield, Connecticut + 15 more

Conditions: Temporomandibular Disorder (TMD)
Interventions: SPM Precursor-Enriched Marine Lipid Supplement, Medium-Chain Triglyceride Supplement; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Primary Open-angle Glaucoma, Ocular Hypertension
Interventions: OPA-6566, Placebo, Latanoprost; Drug
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: Artesia, California • Glendale, California • Roswell, Georgia + 6 more

Conditions: Opioid Use Disorder
Interventions: Psilocybin; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Albuquerque, New Mexico • Brooklyn, New York • New York, New York + 1 more

Conditions: Celiac Disease
Interventions: PRV-015, Placebo; Biological · Other
Lead sponsor: Provention Bio, a Sanofi Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 28
States / cities: Los Angeles, California • Ventura, California • Denver, Colorado + 25 more

Conditions: Scleroderma, Localized, Morphea, Scleroderma, Circumscribed
Interventions: UVA-1 Phototherapy, Placebo; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 6 Years to 95 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Smoking, Heavy Episodic Drinking
Interventions: Tobacco Status Project Intervention, Tobacco Status Project + Alcohol Intervention, nicotine patch; Behavioral · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 25 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Otitis Media Acute
Interventions: PhotoniCare OtoSight Middle Ear Scope; Device
Lead sponsor: PhotoniCare, Inc.; Industry
Eligibility: 6 Months to 4 Years
Enrollment: 188 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Interventions: Maridebart cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 1,105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 59
States / cities: Mobile, Alabama • Gilbert, Arizona • Mesa, Arizona + 53 more

Conditions: Lung Injury, Acute
Interventions: Dose 1 GSK2586881, Dose 2 GSK2586881, Dose 3 GSK2586881, Dose 4 GSK2586881, Placebo (saline); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 13
States / cities: Sacramento, California • Chicago, Illinois • Springfield, Massachusetts + 9 more

Conditions: Tobacco Use
Interventions: Cigarettes with added sucrose; Other
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Inflammation
Interventions: Omega 7 + 3, Omega 3, Placebo; Dietary Supplement
Lead sponsor: Appalachian State University; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Coronary Artery Disease
Interventions: Resolute Integrity Zotarolimus eluting stent, Xience Xpedition everolimus eluting stent, Optical Coherence Tomography (OCT), Intravascular Ultrasound (IVUS); Device
Lead sponsor: Emory University; Other
Eligibility: 30 Years to 80 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions: Computed Tomography, Contrast Agent; Procedure · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: New Brunswick, New Jersey

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: DE-104 ophthalmic solution, low concentration, DE-104 ophthalmic solution, medium concentration, DE-104 ophthalmic solution, high concentration, Placebo, 0.005% latanoprost; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 14
States / cities: Artesia, California • Los Angeles, California • Torrance, California + 9 more

Conditions: Otitis Media
Interventions: PNCRM9, Placebo comparator; Biological
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 2
States / cities: Bloomington, Minnesota • Minneapolis, Minnesota

Conditions: Papulopustular Rosacea
Interventions: Oracea; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Carrollton, Texas

Search by objective public record fields.

iLookOut for Child Abuse -Online Learning Module for Early Childcare Providers

Social Media Intervention for Postpartum Depression

Brain Volume and Cardiac Function in Heart Failure

Citalopram in Treating Postmenopausal Women With Hot Flashes

eMOMS of Rochester

Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)

Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients

Marine Lipids Ease Painful TMD

Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

Psilocybin for Opioid Use Disorder (OUD)

PRV-015 in Gluten-free Diet Non-responsive Celiac Disease

Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea

Smoking Tobacco and Drinking Study

Clinical Development of Deep Learning for the OtoSight

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury

Sugars in Cigarettes

Omega 7 + 3 Combination and Systemic Inflammation

Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels

Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Maternal Immunization To Prevent Infant Otitis Media

Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea